Esketamine (Spravato®) in combination with selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor accepted for use within NHS Scotland

Esketamine nasal spray is approved for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode.


Scottish Medicines Consortium